Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer

With the emergence of various novel therapies including new generation taxane and androgen-targeted therapies, the optimal sequence of systemic treatment in metastatic castration-resistant prostate cancer (mCRPC) patients remains to be defined.

Our aim is to investigate the impact of duration of docetaxel-based chemotherapy and postdocetaxel treatment in mCRPC patients

The medical data of 57 Chinese mCRPC patients who received docetaxel-based chemotherapy in two oncology centers between 2003 and 2012 were reviewed The treatment efficacy and toxicity were determined The potential determinants of efficacy were also determined

Fifty-seven patients (median age 66 years, range 51-82 years) were given docetaxel-based chemotherapy, of whom 48 (84 2%) received 3-weekly docetaxel (52 5-75 mg/m(2)) and nine (15 8%) received weekly docetaxel (35 mg/m(2)) Postdocetaxel treatments were received by 31 (57 4%) patients, including abiraterone in 13 patients and cabazitaxel in one patient The median follow-up time was 14 3 months The median overall survival (OS) and progression-free survival were 20 8 months and 5 8 months, respectively In multivariate analysis, eight cycles or more of chemotherapy [hazard ratio (HR) = 0 151, P < 0 0358], use of postdocetaxel treatment (HR = 0 346, P = 0 0005), and hemoglobin level of

The results suggest that maximizing exposure to docetaxel-based chemotherapy followed by novel therapies would have a favorable survival impact on mCRPC patients

Prostate international 2015 Mar 17 [Epub]

Darren M C Poon, Joyce Ng, Kuen Chan

Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Sir Y K Pao Centre for Cancer, Hong Kong Cancer Institute, Hong Kong ; Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong , Department of Clinical Oncology, State Key Laboratory in Oncology in South China, Sir Y K Pao Centre for Cancer, Hong Kong Cancer Institute, Hong Kong ; Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong , Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong

PubMed   Full Text Article